Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
暂无分享,去创建一个
Kathleen E. Houlahan | Tyler T. Risom | R. Tibshirani | G. Colditz | K. Owzar | K. Deschryver | K. Polyak | Lorraine M. King | C. Maley | E. Hwang | C. Curtis | G. Gupta | A. DeMichele | Shirley X. Zhu | S. Varma | Robert West | T. King | J. Seoane | P. Mcauliffe | Shu Jiang | A. Thompson | A. Storniolo | M. Matusiak | M. Kilgore | Dadong Zhang | E. Hwang | F. Couch | S. Strand | K. Gallagher | Chunfang Zhu | Lauren Anderson | Luis H. Cisneros | Shi Wei | A. Hall | Aziz Khan | D. Veis | J. Nangia | Sucheta A. Srivastava | P. McAuliffe | Joanna S. Lee | J. Tappenden | J. Tseng | J. Marks | S. Vennam | Belén Rivero-Gutiérrez | L. Simpson | T. Hardman | Robyn Burns | C. Straub | R. M. Angelo | Jingqin R Luo | Bryan Harmon | Shi Wei | Jason Wang | Da Ding | Siri H. Strand
[1] Tyler T. Risom,et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma , 2021, Cell.
[2] P. Kristel,et al. Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ , 2021, medRxiv.
[3] K. Chin,et al. Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System , 2020, Molecular Cancer Research.
[4] Tonje G. Lien,et al. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions , 2020, npj Breast Cancer.
[5] K. Polyak,et al. Immune Escape during Breast Tumor Progression , 2020, Cancer Immunology Research.
[6] J. Reis-Filho,et al. Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2020, Clinical Cancer Research.
[7] Ruud H. Brakenhoff,et al. ACE: absolute copy number estimation from low-coverage whole-genome sequencing data , 2019, Bioinform..
[8] L. Shevde,et al. The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.
[9] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[10] Bin Liu,et al. Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.
[11] Jianxin Wang,et al. BPG: Seamless, automated and interactive visualization of scientific data , 2019, BMC Bioinformatics.
[12] R. West,et al. Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ , 2017, Genome Research.
[13] Arnoldo Frigessi,et al. A Bayesian Two-Way Latent Structure Model for Genomic Data Integration Reveals Few Pan-Genomic Cluster Subtypes in a Breast Cancer Cohort , 2018, bioRxiv.
[14] Ambrose J. Carr,et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.
[15] Jesper Eisfeldt,et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants , 2018, bioRxiv.
[16] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[17] Mary E. Edgerton,et al. Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing , 2018, Cell.
[18] T. Sørlie,et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.
[19] T. Sørlie,et al. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. , 2016, Cell reports.
[20] Joel S. Parker,et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..
[21] A. Sahin,et al. A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. , 2015, Cancer research.
[22] Kylie L. Gorringe,et al. Copy number analysis of ductal carcinoma in situ with and without recurrence , 2015, Modern Pathology.
[23] Piet Demeester,et al. FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[24] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[25] George W. Sledge,et al. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.
[26] Serafim Batzoglou,et al. Genome evolution during progression to breast cancer , 2013, Genome research.
[27] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[28] A. Schäffer,et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. , 2012, The American journal of pathology.
[29] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[30] Samantha E. Boyle,et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma , 2012, Breast Cancer Research and Treatment.
[31] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[32] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[33] A. Krasnitz,et al. Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients , 2010, Science Translational Medicine.
[34] Karla Kerlikowske,et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.
[35] J. Thiery,et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[36] A. Vincent-Salomon,et al. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues , 2007, Journal of Clinical Pathology.
[37] Wessel N. van Wieringen,et al. CGHcall: calling aberrations for array CGH tumor profiles , 2007, Bioinform..
[38] Jun Yao,et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Devries,et al. Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ , 2004, Clinical Cancer Research.
[41] Rameen Beroukhim,et al. Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.
[42] M. Gnant,et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[43] Pablo Tamayo,et al. Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Salunga,et al. Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Fernö,et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. , 2001, European journal of cancer.
[46] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[47] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.